fluoxetine and Bipolar Disorder studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.

Research Excerpts

Excerpt	Relevance	Reference
"To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression."	9.10	Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. ( Baker, RW; Beymer, K; Bowden, C; Breier, A; Calabrese, J; Centorrino, F; Dube, S; Evans, AR; Ketter, TA; Mitchell, PB; Risser, R; Sachs, G; Tohen, M; Tollefson, GD; Vieta, E, 2003)
"83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed."	8.93	Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)
"Olanzapine plus fluoxetine combination (OFC) is one of the current approaches for treating the depressive phase of bipolar disorder."	8.89	Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. ( Galvao, TF; Pereira, MG; Silva, MT; Zimmermann, IR, 2013)
" We therefore describe an adolescent sex offender who met DSM-IV criteria for multiple paraphilias (except for the age criterion), bipolar type II disorder, and OCD, whose paraphilic urges and behaviors, depression, and violent obsessions responded to open label fluoxetine after failing to respond to long-term residential treatment."	7.70	An adolescent male with multiple paraphilias successfully treated with fluoxetine. ( Galli, VB; McConville, BJ; McElroy, SL; Raute, NJ, 1998)
"" These behaviors emerged despite gradual dose elevation (2-5 mg/wk), conservative dosing (maximum 40 mg daily), and careful weekly outpatient monitoring of each patient."	6.69	Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. ( Birmaher, B; Go, FS; Malley, EE; Rosenberg, DR, 1998)
" No significant time or dosage effect or time by treatment effect was observed for YMRS."	6.68	Lamotrigine in rapid-cycling bipolar disorder. ( Calabrese, JR; Fatemi, SH; Rapport, DJ; Thuras, P, 1997)
"Chronic administration of olanzapine alone significantly increased firing of LC neurons, while, as reported previously, chronic administration of fluoxetine alone significantly reduced firing of LC neurons."	5.33	Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. ( Barth, VN; Phebus, LA; Rasmussen, K; Seager, MA, 2005)
"Serotonin syndrome is expected to occur more frequently with the increased use of specific serotonin reuptake inhibitors in the treatment of depression."	5.29	[Serotonergic syndrome--in combination therapy with lithium and fluoxetine]. ( Bjørndal, F; Karle, J, 1995)
"In contrast to reports of reduced effectiveness and increased mood conversion rates in patients with rapid cycling bipolar disorder taking antidepressants, we found greater effectiveness and similar hypomania rates during fluoxetine monotherapy in the patients with rapid cycling bipolar II depression versus those with nonrapid cycling bipolar II depression."	5.17	Effectiveness and mood conversion rate of short-term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression. ( Amsterdam, JD; Luo, L; Shults, J, 2013)
"The purpose of this study was to establish whether vomiting bulimic and/or non-bulimic depressive patients, both treated with the serotonin reuptake inhibitor SI-5-HT (fluoxetine), have differing proportions of inorganic components (specifically, sodium, potassium and calcium) in their parotid salivary gland secretions, than in the average population."	5.17	Parotid gland flow activity and inorganic composition in purging bulimic patients treated with fluoxetine. ( Linden, RW; Paszynska, E; Rajewski, A; Slopien, A, 2013)
"Data from a randomized double-blind 8-week study of bipolar I depression were examined post hoc in patients who received placebo (PLA, n = 355), olanzapine (n = 351) (OLZ, 5 to 20 mg/d), or olanzapine-fluoxetine combination (n = 82) (OFC, 6 and 25, 6 and 50, or 12 and 50 mg/d)."	5.12	Clinical relevance of depressive symptom improvement in bipolar I depressed patients. ( Ahl, J; Baker, RW; Brown, E; Perlis, RH; Tohen, M; Williamson, D, 2006)
"To examine the use of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression."	5.10	Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. ( Baker, RW; Beymer, K; Bowden, C; Breier, A; Calabrese, J; Centorrino, F; Dube, S; Evans, AR; Ketter, TA; Mitchell, PB; Risser, R; Sachs, G; Tohen, M; Tollefson, GD; Vieta, E, 2003)
"The effects of fluoxetine and imipramine on the pharmacokinetics and nonpsychiatric side effect profile of quetiapine fumarate were investigated in 26 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a multicenter, two-period, multiple-dose, open-label, randomized trial."	5.10	Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. ( Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002)
"During up to 1 year of olanzapine therapy, either as monotherapy or in combination with lithium and/or fluoxetine, patients with bipolar disorder demonstrated significant improvement in mania and depression symptoms with a favorable safety profile."	5.09	Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. ( Gibson, PJ; Greaney, MG; Grundy, SL; Namjoshi, MA; Sanger, TM; Tohen, MF, 2001)
"83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed."	4.93	Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)
" Several treatments [monoamine oxidase inhibitors (MAOIs), ziprasidone, aripiprazole and risperidone] have limited or no therapeutic activity in bipolar depression."	4.90	Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. ( Cornelius, V; Smith, L; Taylor, DM; Young, AH, 2014)
"The 2 older FDA-approved treatments for bipolar depression, olanzapine-fluoxetine combination (OFC) and quetiapine (QTP) monotherapy, were efficacious (response NNT=4 for OFC, NNT=6 for QTP), but similarly likely to yield harms (OFC weight gain NNH=6; QTP sedation/somnolence NNH=5)."	4.90	Balancing benefits and harms of treatments for acute bipolar depression. ( Calabrese, JR; Citrome, L; Dell'Osso, B; Frye, MA; Ketter, TA; Miller, S, 2014)
"Olanzapine plus fluoxetine combination (OFC) is one of the current approaches for treating the depressive phase of bipolar disorder."	4.89	Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. ( Galvao, TF; Pereira, MG; Silva, MT; Zimmermann, IR, 2013)
"Olanzapine-fluoxetine combination is one of only two products currently approved by the US FDA for the acute treatment of depressive episodes associated with bipolar disorder."	4.87	Olanzapine-fluoxetine combination for the treatment of bipolar depression. ( Citrome, L, 2011)
"Olanzapine/fluoxetine (Symbyax) is an oral once-daily fixed-dose combination of the atypical antipsychotic olanzapine and the selective serotonin reuptake inhibitor (SSRI) fluoxetine that is approved in the US for the treatment of depressive episodes associated with bipolar disorder in adults."	4.84	Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. ( Deeks, ED; Keating, GM, 2008)
"Olanzapine/fluoxetine (Symbyax) is an oral once-daily fixed-dose combination of the atypical antipsychotic olanzapine and the SSRI fluoxetine that is approved in the US for the treatment of depressive episodes associated with bipolar disorder in adults."	4.84	Spotlight on olanzapine/fluoxetine in acute bipolar depression. ( Deeks, ED; Keating, GM, 2008)
"Fluoxetine was the first selective serotonin re-uptake inhibitor to be widely available for treatment of depression and numerous other neuropsychiatric disorders."	4.82	Safety and side effect profile of fluoxetine. ( Wernicke, JF, 2004)
" Here we present a case of a young adult suffering from bipolar disorder who used a combination of two SSRIs (citalopram and fluoxetine) and a monoamine oxidase inhibitor (MAO; moclobemide) with tragic consequences."	3.88	Fatal intoxication with antidepressants: a case with many culprits. ( Goulas, A; Krokos, D; Mastrogianni, O; Orphanidis, A; Raikos, N; Tsepa, A; Zisopoulos, K, 2018)
"We measured [(3)H]AF-DX 384 binding in BA 46 and BA 24 from subjects with bipolar disorders (n = 14), major depressive disorders (n = 19), as well as age- and sex-matched controls (n = 19) and the CNS of rats treated with fluoxetine or imipramine."	3.83	Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. ( Dean, B; Gibbons, AS; Jeon, WJ; Scarr, E, 2016)
" Subsequently, density of [(3)H]LY341495 binding was measured in BA24(anterior cingulate cortex), BA17(visual cortex) and BA46(dorsolateral prefrontal cortex) from subjects with MDD, Bipolar Disorder(BPD), Schizophrenia(SCZ), and controls, as well as rats treated with imipramine (20mg/kg), fluoxetine (10mg/kg), or vehicle."	3.83	Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. ( Dean, B; Gibbons, A; Hopper, S; McOmish, CE; Pavey, G; Scarr, E; Udawela, M, 2016)
" In situ [3H]ketanserin binding and autoradiography was used to measure levels of HTR2A in Brodmann's area (BA) 46 and 24 from people with major depressive disorders (MDD, n = 16), bipolar disorders (BD, n = 14) and healthy controls (n = 14) as well as the central nervous system (CNS) of rats (20 per treatment arm) treated for 10 or 28 d with fluoxetine (10 mg/kg/d) or imipramine (20 mg/kg/d)."	3.80	Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. ( Dean, B; Everall, I; Gibbons, A; Jeon, WJ; Scarr, E; Seo, MS; Tawadros, N, 2014)
"It is suggested that a finding that apparently challenges current practice guidelines, namely that patients with a rapid-cycling pattern of bipolar disorder can take antidepressant monotherapy for months without increasing risk of cycling, may be parsimoniously understood by the way that the investigators defined rapid cycling and by their use of acute-phase fluoxetine monotherapy prior to randomisation to continutaion-phase therapy with fluoxetine, lithium or placebo."	3.79	Antidepressants and rapid-cycling bipolar II disorder: dogma, definitions and deconstructing discrepant data. ( Thase, ME, 2013)
" We report a case with no previous history of bipolar disorder, whereas developed full-blown psychotic manic symptoms soon after switch from fluoxetine to mirtazapine."	3.75	Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features. ( Liang, KY; Liao, SC; Liu, CC, 2009)
"One hundred and twenty-nine children, 2 to 8 years old, with idiopathic autistic spectrum disorder diagnosed by standard instruments (Childhood Austim Ratings Scale and Autism Diagnostic Observation Schedule) were treated with fluoxetine (0."	3.71	Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. ( Burch, S; DeLong, GR; Ritch, CR, 2002)
" We therefore describe an adolescent sex offender who met DSM-IV criteria for multiple paraphilias (except for the age criterion), bipolar type II disorder, and OCD, whose paraphilic urges and behaviors, depression, and violent obsessions responded to open label fluoxetine after failing to respond to long-term residential treatment."	3.70	An adolescent male with multiple paraphilias successfully treated with fluoxetine. ( Galli, VB; McConville, BJ; McElroy, SL; Raute, NJ, 1998)
"Personality disorders are neither particularly stable nor treatment resistant."	2.75	Personality disorders improve in patients treated for major depression. ( Frampton, CM; Joyce, PR; Mulder, RT, 2010)
" Treatment-emergent adverse events with OFC (SP1 and SP2) included increased appetite, increased weight, somnolence, anxiety, insomnia, and depressed mood."	2.74	Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. ( Diaz, B; Fumero, I; Jamal, HH; Mattei, MA; Sutton, VK; Tamayo, JM; Tohen, M; Vieta, E; Zarate, CA, 2009)
"Fluoxetine was given at a fixed dose of 20 mg everyday."	2.71	Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. ( Amsterdam, JD; Brunswick, DJ; Hundert, M; Shults, J, 2004)
"Based on these analyses, patients with bipolar depression receiving olanzapine or OFC for 8 weeks had greater improvement in HRQOL than those receiving placebo."	2.71	Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. ( Baker, RW; Namjoshi, MA; Risser, R; Shi, L; Swindle, R; Tohen, M; Yu, X, 2004)
"" These behaviors emerged despite gradual dose elevation (2-5 mg/wk), conservative dosing (maximum 40 mg daily), and careful weekly outpatient monitoring of each patient."	2.69	Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. ( Birmaher, B; Go, FS; Malley, EE; Rosenberg, DR, 1998)
" Discontinuation for lack of efficacy was lower in BP II (5%) than in UP (12%) patients (p = not significant [NS]), whereas dropouts for adverse events were similar in BP II (11%) and UP (9%) patients."	2.69	Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. ( Amsterdam, JD; Beasley, C; Fawcett, J; Garcia-España, F; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Schweizer, E, 1998)
" No significant time or dosage effect or time by treatment effect was observed for YMRS."	2.68	Lamotrigine in rapid-cycling bipolar disorder. ( Calabrese, JR; Fatemi, SH; Rapport, DJ; Thuras, P, 1997)
"Fluoxetine was statistically significantly superior to placebo in patients with melancholia (endpoint change in the Montgomery-Asberg Depression Rating Scale [MADRS] score, response rates and remission rates)."	2.67	A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. ( Faries, DE; Heiligenstein, JH; Tollefson, GD, 1993)
"Providing an accurate and timely bipolar depression diagnosis is critical for the proper treatment of the patient."	2.50	Acute and maintenance treatments for bipolar depression. ( Ketter, TA, 2014)
"Treatment options for bipolar depression have increased over the last decade, most notably with regulatory approval for olanzapine/fluoxetine combination, quetiapine, and lurasidone."	2.50	Current landscape, unmet needs, and future directions for treatment of bipolar depression. ( Alarcon, RD; Biernacka, JM; Bobo, WV; Choi, DS; Frye, MA; Kung, S; Moore, KM; Prieto, ML; Tye, SJ; Veldic, M, 2014)
"Fluoxetine showed to be efficacious in bipolar depression, confirming its well-known activity in major depressive episodes, with a low percentage of mood switch, despite the general view that antidepressants may increase the rate of manic/hypomanic episodes in BDs."	2.49	Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review. ( Aguglia, E; Di Giannantonio, M; Martinotti, G; Sepede, G; Signorelli, M, 2013)
"OFC trades simplicity of administration for loss of flexibility of dosing and lack of a generic preparation, both of which are available for olanzapine and fluoxetine separately."	2.49	Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression. ( Dubovsky, SL, 2013)
"Despite the considerable burden of bipolar depression, the treatment of this debilitating phase of bipolar disorder is suboptimally addressed by currently available pharmacologic options."	2.43	Clinical highlights in bipolar depression: focus on atypical antipsychotics. ( Calabrese, JR; Elhaj, O; Gajwani, P; Gao, K, 2005)
"This study tested the hypothesis that some patients treated with an antidepressant who develop adverse events (e."	2.39	Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. ( Beasley, CM; Enas, GG; Potvin, JH; Rampey, AH; Tollefson, GD, 1994)
"Fluoxetine has demonstrated, in controlled studies, significantly lower rates of side-effects and treatment dropout than TCAs while showing similar efficacy."	2.39	The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. ( Beuzen, JN; Le Pen, C; Levy, E; Meurgey, F; Ravily, V, 1994)
"Sertraline was found to be modestly efficacious and associated with numerous side effects and discontinuation rates in patients who had previously discontinued fluoxetine."	2.39	Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? ( Cole, JO; Kando, JC; Tohen, M; Weiss, MK; Zarate, CA, 1996)
"This study examined the presence of increased pharmacodynamic tolerance with reduced effectiveness following repeated antidepressant trials over the course of the affective illness in subjects with treatment-responsive bipolar II depression."	1.48	Increase in pharmacodynamic tolerance after repeated antidepressant trials in treatment-responsive bipolar I depressed subjects: An exploratory study. ( Amsterdam, JD; Lorenzo-Luaces, L, 2018)
"Using sleep deprivation (SD) as an animal model of mania, this study aimed to examine the possible relationship between PKC and neuroplasticity in mania."	1.40	Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania. ( Abrial, E; Bétourné, A; Etiévant, A; Haddjeri, N; Lambás-Señas, L; Lucas, G; Scarna, H, 2014)
"Two trials were conducted for bipolar depression (N=410 and 833), and two for manic or mixed episodes (N=136 and 110)."	1.35	The empirical redefinition of the psychometric criteria for remission in bipolar disorder. ( Berk, M; Calabrese, JR; Malhi, GS; Mitchell, PB; Ng, F; Tohen, M; Wang, WV, 2008)
"Criteria for treatment resistance in bipolar depression are commonly based on concepts stemming from treatment resistance as defined for unipolar depression, an approach that proved to be inadequate."	1.35	Treatment-resistant bipolar depression: towards a new definition. ( Colom, F; Girardi, P; Kotzalidis, GD; Mazzarini, L; Pacchiarotti, I; Sanchez-Moreno, J; Vieta, E, 2009)
"Chronic administration of olanzapine alone significantly increased firing of LC neurons, while, as reported previously, chronic administration of fluoxetine alone significantly reduced firing of LC neurons."	1.33	Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. ( Barth, VN; Phebus, LA; Rasmussen, K; Seager, MA, 2005)
" Reduction of the fluoxetine dosage to 10 mg twice weekly was associated with the attainment of euthymia in 18 days."	1.31	Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania. ( Devitt, PJ; Megna, JL, 2001)
" A full pharmacokinetic time profile of lithium was obtained."	1.31	Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. ( Beijnen, JH; Kerbusch, T; Mathôt, RA; Meesters, EW; Otten, HM; Schellens, JH; van Kan, HJ, 2002)
"Serotonin syndrome is expected to occur more frequently with the increased use of specific serotonin reuptake inhibitors in the treatment of depression."	1.29	[Serotonergic syndrome--in combination therapy with lithium and fluoxetine]. ( Bjørndal, F; Karle, J, 1995)
"Data from an intensive observational drug utilization study were analyzed to determine whether patients who received the combination of fluoxetine and lithium had more and different adverse events as compared with those receiving fluoxetine alone."	1.29	Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. ( Bauer, M; Linden, M; Schaaf, B; Weber, HJ, 1996)
" Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents."	1.28	Mania associated with fluoxetine treatment in adolescents. ( King, CA; Naylor, MW; Venkataraman, S, 1992)

Research

Studies (190)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Change From Baseline in Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) Up to Week 8

Timeframe	Studies, this research(%)	All Research%
pre-1990	11 (5.79)	18.7374
1990's	54 (28.42)	18.2507
2000's	65 (34.21)	29.6817
2010's	54 (28.42)	24.3611
2020's	6 (3.16)	2.80

Authors	Studies
Patel, RS	1
Veluri, N	1
Patel, J	1
Patel, R	1
Machado, T	1
Diler, R	1
Strawbridge, R	1
Kurana, S	1
Kerr-Gaffney, J	1
Jauhar, S	1
Kaufman, KR	1
Yalin, N	1
Young, AH	2
Croatto, G	1
Vancampfort, D	1
Miola, A	1
Olivola, M	1
Fiedorowicz, JG	1
Firth, J	1
Alexinschi, O	1
Gaina, MA	1
Makkai, V	1
Soares, FC	1
Cavaliere, L	1
Vianello, G	1
Stubbs, B	1
Fusar-Poli, P	1
Carvalho, AF	1
Vieta, E	10
Cortese, S	1
Shin, JI	1
Correll, CU	2
Solmi, M	2
Garcia-Rodriguez, L	1
Burton, DJ	1
Leonards, CA	1
Davey, CG	1
Yildiz, A	1
Siafis, S	1
Mavridis, D	1
Leucht, S	1
Goulas, A	1
Raikos, N	1
Krokos, D	1
Mastrogianni, O	1
Orphanidis, A	1
Zisopoulos, K	1
Tsepa, A	1
Chang, HH	1
Chen, PS	2
Cheng, YW	1
Wang, TY	2
Yang, YK	2
Lu, RB	3
Abou Kassm, S	1
Naja, W	1
Saiardi, A	1
Mudge, AW	1
Yoon, W	1
Shon, SH	1
Hong, Y	1
Joo, YH	1
Lee, JS	1
Amsterdam, JD	11
Lorenzo-Luaces, L	1
Zubair, UB	1
Mansoor, S	1
Akaltun, İ	1
Ayaydin, H	1
Martinotti, G	1
Sepede, G	1
Signorelli, M	1
Aguglia, E	1
Di Giannantonio, M	1
Thase, ME	3
Luo, L	2
Shults, J	7
Paszynska, E	1
Linden, RW	1
Slopien, A	1
Rajewski, A	1
Xenitidis, K	2
Campbell, C	2
Eppel, AB	1
Özcan, Ö	1
Özdemir, S	1
Kütük, ÖM	1
Miller, MC	2
McIntyre, RS	1
Cha, DS	1
Kim, RD	1
Mansur, RB	1
Dean, B	3
Tawadros, N	1
Seo, MS	1
Jeon, WJ	2
Everall, I	1
Scarr, E	3
Gibbons, A	2
Ketter, TA	5
Cristancho, MA	1
Lee, SY	1
Chen, SL	1
Chang, YH	1
Huang, SY	2
Tzeng, NS	2
Wang, CL	1
Wang, LJ	1
Lee, IH	1
Chen, KC	1
Hong, JS	1
Taylor, DM	1
Cornelius, V	1
Smith, L	1
McElroy, SL	6
Citrome, L	3
Frye, MA	4
Prieto, ML	1
Bobo, WV	1
Kung, S	1
Veldic, M	1
Alarcon, RD	1
Moore, KM	1
Choi, DS	1
Biernacka, JM	1
Tye, SJ	1
Miller, S	1
Dell'Osso, B	1
Calabrese, JR	7
Abrial, E	1
Bétourné, A	1
Etiévant, A	1
Lucas, G	1
Scarna, H	1
Lambás-Señas, L	1
Haddjeri, N	1
Detke, HC	1
DelBello, MP	1
Landry, J	1
Usher, RW	1
Vázquez, GH	1
Holtzman, JN	1
Tondo, L	1
Baldessarini, RJ	3
Ford, N	1
Ludbrook, G	1
Galletly, C	1
Gibbons, AS	1
McOmish, CE	1
Pavey, G	1
Hopper, S	1
Udawela, M	1
Youssef, NA	1
Ara, A	1
Bhat, I	1
Cawkwell, P	1
Lawler, A	1
Maneta, E	1
Coffey, BJ	1
Jha, S	1
Kumar, P	1
Kumar, R	2
Das, A	1
Veronese, N	1
Zaninotto, L	1
van der Loos, ML	1
Gao, K	3
Schaffer, A	1
Reis, C	1
Normann, C	1
Anghelescu, IG	1
Liu, CC	2
Liang, KY	1
Liao, SC	1
Deeks, ED	2
Keating, GM	2
Brown, E	2
Dunner, DL	1
Keck, PE	4
Adams, DH	3
Degenhardt, E	1
Tohen, M	15
Houston, JP	2
Azorin, JM	1
Kaladjian, A	1
Nierenberg, AA	1
Berk, M	5
Wang, W	2
Colom, F	3
Denizot, H	1
Laporte, F	1
Llorca, PM	1
Tamayo, JM	1
Sutton, VK	2
Mattei, MA	1
Diaz, B	1
Jamal, HH	1
Zarate, CA	3
Fumero, I	1
Kemp, DE	2
Ganocy, SJ	2
Muzina, DJ	1
Xia, G	1
Findling, RL	1
Cruz, N	1
Sanchez-Moreno, J	3
Torres, F	1
Goikolea, JM	1
Valentí, M	1
Grunze, H	1
Fajutrao, L	1
Paulsson, B	2
Liu, S	1
Locklear, J	2
Pacchiarotti, I	1
Mazzarini, L	1
Girardi, P	1
Kotzalidis, GD	1
Mulder, RT	4
Joyce, PR	4
Frampton, CM	1
Benazzi, F	1
Barraco, A	1
Perlis, RH	3
Fijal, B	1
Farmen, M	1
Breier, A	2
Suppes, T	1
Günther, O	1
Ekman, M	1
Miltenburger, C	1
Chatterton, ML	1
Aström, M	1
Eppel, A	1
Brecher, M	1
Carlson, BX	1
Edwards, S	1
Eudicone, JM	1
Evoniuk, G	1
Jansen, W	1
Leon, AC	1
Minkwitz, M	1
Pikalov, A	1
Stassen, HH	1
Szegedi, A	1
Van Willigenburg, AP	1
Savitz, JB	1
Nugent, AC	1
Bogers, W	1
Roiser, JP	1
Bain, EE	1
Neumeister, A	1
Manji, HK	1
Cannon, DM	1
Marrett, S	1
Henn, F	1
Charney, DS	1
Drevets, WC	1
Aggarwal, A	1
Sharma, DD	1
Sharma, RC	1
Hung Chi, M	1
Hua Chang, H	1
Chou, KR	1
Chun Tsai, H	1
Kuang Yang, Y	1
See Chen, P	1
Lin, HY	1
Lin, CC	1
Raghunath, A	1
Silva, MT	1
Zimmermann, IR	1
Galvao, TF	1
Pereira, MG	1
Dubovsky, SL	1
DeLong, GR	1
Ritch, CR	1
Burch, S	1
Lee, MS	1
Lessell, S	1
Bowden, CL	2
Bates, G	1
Willson, SW	1
Shelton, RC	2
McKenzie, H	1
Dodd, S	1
Luty, SE	3
McKenzie, JM	3
Miller, AL	2
Rogers, GR	1
Kennedy, MA	2
Calabrese, J	1
Sachs, G	1
Bowden, C	1
Mitchell, PB	2
Centorrino, F	1
Risser, R	2
Baker, RW	3
Evans, AR	1
Beymer, K	1
Dube, S	2
Tollefson, GD	4
Brunswick, DJ	2
Hundert, M	1
Shi, L	1
Namjoshi, MA	2
Swindle, R	1
Yu, X	1
McIntosh, VV	1
Carter, FA	1
Bulik, CM	1
Sullivan, PF	1
Pae, CU	1
Lee, CU	1
Lee, SJ	1
Lee, C	1
Paik, IH	1
Wernicke, JF	2
Kaplan, GB	1
McRoberts, RL	1
Smokler, HJ	1
Hennen, J	1
Martínez-Arán, A	1
Yatham, LN	1
Seager, MA	1
Barth, VN	1
Phebus, LA	1
Rasmussen, K	1
Porter, RJ	1
Corya, SA	2
Altshuler, LL	1
Case, M	2
Briggs, SD	2
Elhaj, O	1
Gajwani, P	1
Williams, AB	1
Adetunji, BA	1
Reeves, RR	1
Ladner, ME	1
Williamson, D	1
Ahl, J	1
Lin, DY	1
Case, MG	1
Williamson, DJ	2
Tohen, MF	2
Brown, EB	1
Deldar, A	1
Moreira-Almeida, A	1
Pietrobon, R	1
Ceylan, ME	1
Alpsan, MH	1
Łojko, D	1
Rybakowski, JK	1
Mistler, LA	1
Brunette, MF	1
Rosenberg, SD	1
Vidaver, RM	1
Luckoor, R	1
Iber, M	1
Malatynska, E	1
Pinhasov, A	1
Crooke, JJ	1
Smith-Swintosky, VL	1
Brenneman, DE	1
Ng, F	1
Wang, WV	1
Malhi, GS	1
Van Campen, LE	1
Bánki, CM	1
Preskorn, SH	2
Settle, EC	1
Settle, GP	1
Seifritz, E	1
Hatzinger, M	1
Müller, MJ	1
Hemmeter, U	1
Holsboer-Trachsler, E	1
Campbell, M	1
Cueva, JE	1
Karle, J	1
Bjørndal, F	1
el-Yazigi, A	1
Chaleby, K	1
Gad, A	1
Raines, DA	1
Montgomery, DB	1
Roberts, A	1
Green, M	1
Bullock, T	1
Baldwin, D	1
Montgomery, SA	1
Sacchetti, E	1
Conte, G	1
Guarneri, L	1
Stoll, AL	2
Mayer, PV	1
Kolbrener, M	1
Goldstein, E	1
Suplit, B	1
Lucier, J	1
Cohen, BM	1
Rampey, AH	1
Beasley, CM	1
Enas, GG	1
Potvin, JH	1
Le Pen, C	1
Levy, E	1
Ravily, V	1
Beuzen, JN	1
Meurgey, F	1
Rothschild, AJ	1
Samson, JA	1
Bessette, MP	1
Carter-Campbell, JT	1
Heiligenstein, JH	1
Faries, DE	1
Hopwood, SE	1
Bogle, S	1
Wildgust, HJ	1
Berthier, ML	2
Kulisevsky, J	2
Jerome, L	2
Mundo, E	1
Ronchi, P	1
Bellodi, L	1
Terao, T	1
Kando, JC	1
Weiss, MK	1
Cole, JO	2
Bauer, M	1
Linden, M	1
Schaaf, B	1
Weber, HJ	1
Manus, A	1
Koopowitz, LF	1
Szabo, CP	1
Sabbe, B	1
van Hoof, J	1
Hulstijn, W	1
Zitman, F	1
Maes, M	1
De Meester, I	1
Scharpe, S	1
Desnyder, R	1
Ranjan, R	1
Meltzer, HY	1
Kmetz, GF	1
Collins, DJ	1
Rudnick, A	1
Modai, I	1
Zelikovski, A	1
Benedetti, F	1
Barbini, B	1
Lucca, A	1
Campori, E	1
Colombo, C	1
Smeraldi, E	1
Arya, DK	1
Fatemi, SH	1
Rapport, DJ	1
Thuras, P	1
Brent, NB	1
Wisner, KL	1
Damore, J	1
Stine, J	1
Brody, L	1
Go, FS	1
Malley, EE	1
Birmaher, B	1
Rosenberg, DR	1
Boerlin, HL	1
Gitlin, MJ	1
Zoellner, LA	1
Hammen, CL	1
Galli, VB	1
Raute, NJ	1
McConville, BJ	1
Garcia-España, F	1
Fawcett, J	1
Quitkin, FM	1
Reimherr, FW	1
Rosenbaum, JF	2
Schweizer, E	1
Beasley, C	1
Smith, DL	1
Wenegrat, BG	1
Megna, JL	1
Devitt, PJ	1
Sanger, TM	1
Grundy, SL	1
Gibson, PJ	1
Greaney, MG	1
Gonzalez-Pinto, A	1
Imaz, H	1
De Heredia, JL	1
Gutierrez, M	1
Micó, JA	1
Grunhaus, L	1
Hirschman, S	1
Dolberg, OT	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder[NCT00844857]	Phase 4	291 participants (Actual)	Interventional	2009-04-30	Completed
The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822]		550 participants (Anticipated)	Observational	2022-02-18	Recruiting
Bipolar Depression Assessment Study on Tx Response[NCT00191399]	Phase 4	150 participants	Interventional	2004-05-31	Completed
Relapse Prevention of Bipolar Type-II Disorder[NCT00044616]	Phase 4	180 participants	Interventional	2001-02-28	Completed
Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332]	Phase 4	20 participants (Actual)	Interventional	2007-01-31	Completed
A Controlled Trial of Citalopram Added to Methylphenidate in Youth With Severe Mood Dysregulation[NCT00794040]	Phase 2	103 participants (Actual)	Interventional	2008-11-17	Completed
An Investigation of the Antidepressant Efficacy of a Dopamine Agonist With Neurotrophic Properties in Bipolar Disorder[NCT00025792]	Phase 2	200 participants	Interventional	2001-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

ALT/SGPT LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in Electrocardiogram (ECG) QTcF Interval Up to Week 8

Intervention	units/Liter (U/L) (Least Squares Mean)
Olanzapine/Fluoxetine Combination	7.63
Placebo	0.46

QTcF is defined as ECG QT interval corrected for heart rate using the Fridericia correction factor. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in Prolactin Up to Week 8

Intervention	millisecond (msec) (Least Squares Mean)
Olanzapine/Fluoxetine Combination	8.19
Placebo	-1.07

Prolactin LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in Symptoms of Attention-Deficit/Hyperactivity Disorder Up to Week 8

Intervention	microgram/Liter (μg/L) (Least Squares Mean)
Olanzapine/Fluoxetine Combination	8.66
Placebo	0.70

Attention Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version (ADHDRS-IV-PI): Investigator Administered and Scored measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Scores range: 0 to 54. The LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline up to Week 8

Change From Baseline in the CDRS-R Total Score Up to Week 8

Intervention	units on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination	-4.31
Placebo	-3.57

CDRS-R Total score measure the presence and severity of depression in children and consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. Total scores range from 17 to 113. In general, scores < 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS mean was adjusted for baseline, country, and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8

Intervention	units on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination	-28.57
Placebo	-23.38

CDRS-R Total score measures the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) mean was adjusted for baseline, country, treatment, visit, and treatment times (*) visit interaction. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in the Clinical Global Impression Scale - Bipolar Version (CGI-BP) Score at Week 8

Intervention	units on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination	-28.43
Placebo	-23.40

CGI-BP measures severity of illness for bipolar illness. Scores range: 1 (normal, not ill at all) to 7 (among the most extremely ill patients). LS mean was adjusted for baseline, country, treatment, visit, and treatment * visit interaction. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in the Quality of Life Questionnaire for Children and Adolescents (KINDL) Kid and Kiddo Combined Scale Up to Week 8

Intervention	units on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination	-2.21
Placebo	-1.83

The KINDL consists of 24 Likert-scale items. Kid-KINDL was administered to ages 8-11 and Kiddo-KINDL to ages 12-16. Total scores were standardized to a 0 (lowest quality of life) to 100 (highest quality of life). LS mean was adjusted for baseline, country, and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in the Quality of Life Questionnaire for Children and Adolescents (KINDL) Parent Scale Up to Week 8

Intervention	units on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination	12.83
Placebo	7.91

The KINDL consists of 24 Likert-scale items. Total scores were standardized to a 0 (lowest quality of life) to 100 (highest quality of life). LS mean was adjusted for baseline, country, and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in the YMRS Total Score at Week 8

Intervention	units on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination	15.98
Placebo	10.88

The YMRS is an 11-item scale measuring the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total scores ranges: 0 to 60. LS mean was adjusted for baseline, country, treatment, visit, and treatment * visit interaction. (NCT00844857)
Timeframe: Baseline, Week 8

Change From Baseline in Weight Up to Week 8

Intervention	units on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination	-2.02
Placebo	-1.57

Weight LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Percentage of Participants With at Least One Incident of Worsening of Mania Up to Week 8

Intervention	kilogram (kg) (Least Squares Mean)
Olanzapine/Fluoxetine Combination	4.37
Placebo	0.50

Worsening of mania was defined as YMRS score of ≥20 and a CGI severity of mania score of ≥ 5 at the same visit. The YMRS is an 11-item scale measuring severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe) with remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. CGI measures severity of the participant's overall severity of bipolar symptoms and scores range from 1 (normal) to 7 (among the most extremely ill participants). (NCT00844857)
Timeframe: Baseline up to Week 8

Percentage of Participants With at Least One Treatment-Emergent Incident of Akathisia Up to Week 8

Intervention	percentage of participants (Number)
Olanzapine/Fluoxetine Combination	1.2
Placebo	0.0

Akathisia was measured using the Barnes Akathisia Rating Scale where the global scores range from 0 (absent) to 5 (severe) and a score ≥ 2 is considered abnormal. (NCT00844857)
Timeframe: Baseline up to Week 8

Percentage of Participants With at Least One Treatment-Emergent Incident of Dyskinesia Up to Week 8

Intervention	percentage of participants (Number)
Olanzapine/Fluoxetine Combination	1.3
Placebo	0.0

Dyskinesia was measured using the Abnormal Involuntary Movement Scale (AIMS) a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 through 10 are rated on a 5-point scale: 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Items 11 and 12 are yes/no questions regarding the dental condition of a patient. Total score (0-40) is obtained by adding the scores of the first 10 items. An abnormal result is defined as having a score ≥3 for at least 1 of the first 7 items or a score ≥2 for at least two of the first 7 items. (NCT00844857)
Timeframe: Baseline, Week 8

Percentage of Participants With at Least One Treatment-Emergent Incident of Parkinsonism Up to Week 8

Intervention	percentage of participants (Number)
Olanzapine/Fluoxetine Combination	0.6
Placebo	0.0

Parkinsonism was measured using the Simpson-Angus Scale with a total scores range from 0 to 40. A score > 3 was considered abnormal. Simpson-Angus Scale consists of 10 items, each rated on a 5-point scale, 0 (complete absence of the condition) to 4 (presence of the condition in extreme form). (NCT00844857)
Timeframe: Baseline, Week 8

Percentage of Participants With Remission Up to Week 8

Intervention	percentage of participants (Number)
Olanzapine/Fluoxetine Combination	0.6
Placebo	1.3

Remission is defined as a CDRS-R total score less than or equal to (≤)28, and Young Mania Rating Scale (YMRS) total score ≤ 8 and Clinical Global Impressions-Bipolar Version (CGI-BP) total score ≤3. CDRS-R is a 17-item scale measuring presence/severity of depression in children and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. Scores range: 17 to 113. Scores <20 indicate an absence of depression, scores 20 to 30 indicate borderline depression, scores 40 to 60 indicate moderate depression. The YMRS is an 11-item scale measuring severity of manic episodes; 4 items are rated on a scale from 0 (symptoms not present) to 8 (symptom extremely severe) with remaining items rated on a scale from 0 (symptoms not present) to 4 (symptom extremely severe). YMRS score ranges from 0 to 60. CGI-BP measures participant's overall severity of bipolar symptoms. Scores range: 1 (normal, not at all ill ) to 7 (among the most extremely ill participants). (NCT00844857)
Timeframe: Baseline up to Week 8

Percentage of Participants With Response Up to Week 8

Intervention	percentage of participants (Number)
Olanzapine/Fluoxetine Combination	59.0
Placebo	43.4

Response is defined as a CDRS-R total score greater than or equal to (≥)50% reduction from baseline and YMRS elevated mood score ≤2. CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. Scores range: 17 to 113. In general, <20 indicate an absence of depression, scores 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptoms not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptoms not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. (NCT00844857)
Timeframe: Baseline up to Week 8

Change From Baseline in Fasting Metabolic Parameters Up to Week 8

Intervention	percentage of participants (Number)
Olanzapine/Fluoxetine Combination	78.2
Placebo	59.2

Fasting glucose, fasting cholesterol and fasting triglycerides. LS means were adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Percentage of Participants in Each Improvement Category Up to Week 8

Intervention	millimoles/liter (mmol/L) (Least Squares Mean)
	Fasting Glucose (157, 79)	Fasting Cholesterol (158, 81)	Fasting Triglycerides (158, 81)
Olanzapine/Fluoxetine Combination	0.03	0.42	0.40
Placebo	0.03	-0.11	-0.04

CDRS-R scores: No/low improvement is < 25 percent (%) of maximum reduction from baseline. Mild improvement: maximum reduction from baseline on CDRS-R score ≥ 25% up to <50% and YMRS elevated mood score ≤ 2. Moderate improvement: maximum reduction from baseline on CDRS-R score ≥50% and <75% and YMRS elevated mood score ≤ 2. Major improvement: maximum reduction from baseline on CDRS-R score ≥75% and YMRS elevated mood score ≤ 2. CDRS-R measures presence/severity of depression in children. Scale is 17 items scored 1-to-5- or 1-to-7. Rating of 1 indicates normal function. Scores range: 17 to 113. Scores < 20 absence of depression, scores 20 to 30 borderline depression, scores 40 to 60 indicate moderate depression. YMRS is an 11-item scale that measures severity of manic episodes. Four items rated 0 (symptoms not present) to 8 (symptom extremely severe). Remaining items rated 0 (symptoms not present) to 4 (symptom extremely severe). Score range: 0 to 60. (NCT00844857)
Timeframe: Baseline up to Week 8

Percentage of Participants With Treatment Emergent Suicidal Ideation or Behavior Up to Week 8

Intervention	percentage of participants (Number)
	No or Low Improvement	Mild Improvement	Moderate Improvement	Major Improvement
Olanzapine Plus Fluoxetine Combination	12.8	9.0	21.8	56.4
Placebo	22.4	18.4	18.4	40.8

"Columbia-Suicide Severity Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Percentage of participants with suicidal ideation, behavior, and acts are provided. Suicidal ideation: a yes answer to any 1 of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act: a yes answer to actual attempt or completed suicide." (NCT00844857)
Timeframe: Baseline up to Week 8

Change From Baseline Montgomery Asberg Depression Rating Scale

Intervention	percentage of participants (Number)
	Total Suicidal Ideation (1 - 5)	Total Suicidal Behavior (6 - 10)	Total Suicidal Ideation or Behavior (1 - 10)
Olanzapine/Fluoxetine Combination	10.6	1.8	10.6
Placebo	15.5	2.4	15.5

Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks

Weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8

Intervention	units on a scale (Mean)
Arm 1	-15.5
Arm 2	-15.5

Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks

"Percentage of Participants That Much Improved (Score of 2) in, or Completely Recovered (Score of 1) From Their Irritability Severity, as Measured With the Clinical Global Impression-Improvement (CGI-I)."

Intervention	kilograms (Mean)
	Baseline	Week 1	Week 4	Week 6	Week 8
Arm 1- ODT	76.0	77.4	77.8	78.9	79.1
Arm 2- SOT	76.1	77.6	78.3	79.4	80.1

"A measure of change of irritability severity taking the baseline before randomization as a reference. Scores range 1 to 8, in which 1=Completely recovered,... 5=Unchanged,... 8=Much worse.~Percentage of participants who responded are based on an estimation and might not match exactly with discrete numbers of participants based on the denominator." (NCT00794040)
Timeframe: Collected weekly during the 8-week trial. The 8th-week outcome is reported.

Anxiety Symptoms at 8th Week of Trial

Intervention	estimated percentage of participants (Number)
Add-on Citalopram Following Optimized Methylphenidate	35
Add-on Placebo Following Optimized Methylphenidate	6

Difference in anxiety symptoms at 8th week of trial as measured with the Pediatric Anxiety Rating Scale (PARS) with scores ranging 0-25. Higher values represent a worse outcome. (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.

Depressive Symptoms at 8th Week of Trial

Intervention	units on a scale (Mean)
Add-on Citalopram Following Optimized Methylphenidate	12.0
Add-on Placebo Following Optimized Methylphenidate	13.4

Difference in depressive symptoms at 8th week of trial as measured with Children's Depression Rating Scale (CDRS) with scores ranging 17-113, where scores >40 are considered over the clinical threshold, and scores <28 are considered within the healthy range. (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.

Functional Impairment at 8th Week of Trial

Intervention	units on a scale (Mean)
Add-on Citalopram Following Optimized Methylphenidate	28.6
Add-on Placebo Following Optimized Methylphenidate	30.1

Difference in functional impairment at 8th week of trial as measured with Children's Global Impression Scale (CGAS) with scores ranging from 1=Most impaired to 100=Not impaired at all. (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.

Irritability Severity at 8th Week of Trial.

Intervention	units on a scale (Mean)
Add-on Citalopram Following Optimized Methylphenidate	52.6
Add-on Placebo Following Optimized Methylphenidate	47.2

Clinical Global Impression-Severity (CGI-S): A measure of severity of irritability scale (from 1=Normal, not at all ill to 7=Among the most extremely ill patients). (NCT00794040)
Timeframe: Collected weekly during the 8th week trial. The 8th-week outcome is reported.

Article	Year
Second-Generation Antipsychotics in Management of Acute Pediatric Bipolar Depression: A Systematic Review and Meta-analysis. Journal of child and adolescent psychopharmacology, 2021, Volume: 31, Issue:8 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brief Psychiatric Rating Scale; Child; Drug	2021
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder. Acta psychiatrica Scandinavica, 2022, Volume: 146, Issue:4 Topics: Aripiprazole; Bipolar Disorder; Citalopram; Fluoxetine; Humans; Lamotrigine; Olanzapine; Quetiapine	2022
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials. Molecular psychiatry, 2023, Volume: 28, Issue:1 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder	2023
Effectiveness of atypical antipsychotics for unipolar and bipolar depression in adolescents and young adults: A systematic review and meta-analysis. Journal of affective disorders, 2023, 10-15, Volume: 339 Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Fluoxetine; Humans; Lurasidone Hydrochlor	2023
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. The lancet. Psychiatry, 2023, Volume: 10, Issue:9 Topics: Adult; Bipolar Disorder; Depression; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxe	2023
Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:8 Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Fluoxetine; Humans; Selective Serotonin	2013
A review of FDA-approved treatment options in bipolar depression. CNS spectrums, 2013, Volume: 18 Suppl 1 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzhydryl Co	2013
Acute and maintenance treatments for bipolar depression. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:4 Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depression; Dibenzothiazepin	2014
Drug safety evaluation of olanzapine/fluoxetine combination. Expert opinion on drug safety, 2014, Volume: 13, Issue:8 Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Di	2014
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta psychiatrica Scandinavica, 2014, Volume: 130, Issue:6 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder;	2014
Treatment of bipolar depression: making sensible decisions. CNS spectrums, 2014, Volume: 19 Suppl 1 Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De	2014
Current landscape, unmet needs, and future directions for treatment of bipolar depression. Journal of affective disorders, 2014, Volume: 169 Suppl 1 Topics: Anticonvulsants; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiazepines; Drug	2014
Balancing benefits and harms of treatments for acute bipolar depression. Journal of affective disorders, 2014, Volume: 169 Suppl 1 Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diben	2014
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS spectrums, 2016, Volume: 21, Issue:5 Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip	2016
Spotlight on olanzapine/fluoxetine in acute bipolar depression. CNS drugs, 2008, Volume: 22, Issue:9 Topics: Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans	2008
An update on the treatment of bipolar depression. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:2 Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Di	2009
An analysis of the efficacy of treatments for bipolar depression. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 5 Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Affect; Anticonvulsants; Antidepressive Agen	2008
Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder. The Journal of clinical psychiatry, 2008, Volume: 69 Suppl 5 Topics: Acute Disease; Affect; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agent	2008
[Pharmacotherapy of children with depressive disorders]. Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2009, Volume: 16, Issue:8 Topics: Adolescent; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Child; Co	2009
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. The international journal of neuropsychopharmacology, 2010, Volume: 13, Issue:1 Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Dibenz	2010
Treatment options for bipolar depression: a systematic review of randomized, controlled trials. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:5 Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Di	2010
Clinical practice. Bipolar disorder--a focus on depression. The New England journal of medicine, 2011, Jan-06, Volume: 364, Issue:1 Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disord	2011
Olanzapine-fluoxetine combination for the treatment of bipolar depression. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:17 Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Di	2011
Olanzapine plus fluoxetine for bipolar disorder: a systematic review and meta-analysis. Journal of affective disorders, 2013, Apr-25, Volume: 146, Issue:3 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans; Rand	2013
Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:2 Topics: Animals; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Fluoxeti	2013
The combination of olanzapine and fluoxetine in mood disorders. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:7 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Drug Therapy, Com	2003
Antidepressant monotherapy for bipolar type II major depression. Bipolar disorders, 2003, Volume: 5, Issue:6 Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Bipolar Disorder; Clinical Trials as Topic;	2003
Safety and side effect profile of fluoxetine. Expert opinion on drug safety, 2004, Volume: 3, Issue:5 Topics: Adolescent; Adult; Biotransformation; Bipolar Disorder; Cardiovascular Diseases; Child; Comorbidity;	2004
Treatment options for bipolar depression. The Journal of clinical psychiatry, 2005, Volume: 66 Suppl 1 Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dep	2005
Clinical highlights in bipolar depression: focus on atypical antipsychotics. The Journal of clinical psychiatry, 2005, Volume: 66 Suppl 5 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dibenzothiaze	2005
Olanzapine/fluoxetine combination for bipolar depression. Expert review of neurotherapeutics, 2006, Volume: 6, Issue:1 Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combin	2006
[Olanzapine: a second generation antipsychotic drug and an "atypical" mood stabilizer?]. Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata, 2007, Volume: 22, Issue:4 Topics: Affect; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Benzodiaze	2007
Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. Drugs, 2008, Volume: 68, Issue:8 Topics: Acute Disease; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Drug Combinations; Drug	2008
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II. Journal of the American Academy of Child and Adolescent Psychiatry, 1995, Volume: 34, Issue:10 Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder	1995
Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:3 Topics: Adult; Antidepressive Agents, Tricyclic; Bipolar Disorder; Depressive Disorder; Female; Fluoxetine;	1994
The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. Journal of affective disorders, 1994, Volume: 31, Issue:1 Topics: Antidepressive Agents, Tricyclic; Bipolar Disorder; Cost of Illness; Cost-Benefit Analysis; Depressi	1994
Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline? The Journal of clinical psychiatry, 1996, Volume: 57, Issue:2 Topics: 1-Naphthylamine; Adolescent; Adult; Bipolar Disorder; Depressive Disorder; Drug Tolerance; Female; F	1996
[Clinical criteria for choosing an antidepressive drug]. L'Encephale, 1995, Volume: 21 Spec No 4 Topics: Affective Disorders, Psychotic; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Fluoxe	1995

Article	Year
Effectiveness and mood conversion rate of short-term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression. Journal of clinical psychopharmacology, 2013, Volume: 33, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bipolar Disorder; Dose-Res	2013
Parotid gland flow activity and inorganic composition in purging bulimic patients treated with fluoxetine. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2013, Volume: 14, Issue:8 Topics: Adult; Bipolar Disorder; Bulimia; Calcium; Female; Fluoxetine; Humans; Parotid Gland; Potassium; Sal	2013
Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naïve patients with bipolar II disorder after a twelve-week pharmacological intervention. Acta psychiatrica Scandinavica, 2015, Volume: 131, Issue:2 Topics: Adult; Affect; Bipolar Disorder; Body Mass Index; Brain-Derived Neurotrophic Factor; Cholesterol; Fe	2015
Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, Volume: 54, Issue:3 Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Child; Double-Blind Method; Dru	2015
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. The international journal of neuropsychopharmacology, 2009, Volume: 12, Issue:6 Topics: Adolescent; Adult; Benzodiazepines; Bipolar Disorder; Calcium Channel Blockers; Dose-Response Relati	2009
Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. Journal of affective disorders, 2009, Volume: 119, Issue:1-3 Topics: Antidepressive Agents, Second-Generation; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Dr	2009
Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico. Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4 Topics: Adult; Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Female; Fluoxeti	2009
Personality disorders improve in patients treated for major depression. Acta psychiatrica Scandinavica, 2010, Volume: 122, Issue:3 Topics: Adult; Antidepressive Agents; Bipolar Disorder; Comorbidity; Depressive Disorder, Major; Dose-Respon	2010
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression. The Journal of clinical psychiatry, 2010, Volume: 71, Issue:5 Topics: Adult; Antidepressive Agents, Second-Generation; Benzodiazepines; Bipolar Disorder; Dopamine beta-Hy	2010
Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. The American journal of psychiatry, 2010, Volume: 167, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bip	2010
Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:3 Topics: Adult; Affect; Aged; Aged, 80 and over; Bipolar Disorder; Depressive Disorder, Major; Female; Fluoxe	2010
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. Journal of affective disorders, 2011, Volume: 130, Issue:1-2 Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benz	2011
Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. The British journal of psychiatry : the journal of mental science, 2013, Volume: 202, Issue:4 Topics: Adult; Affect; Antidepressive Agents; Bipolar Disorder; Double-Blind Method; Female; Fluoxetine; Hum	2013
Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:4 Topics: Adult; Age Factors; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc	2003
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Archives of general psychiatry, 2003, Volume: 60, Issue:11 Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Diso	2003
Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depression - low manic switch rate. Bipolar disorders, 2004, Volume: 6, Issue:1 Topics: Adult; Bipolar Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Huma	2004
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clinical therapeutics, 2004, Volume: 26, Issue:1 Topics: Adult; Benzodiazepines; Bipolar Disorder; Drug Combinations; Female; Fluoxetine; Humans; Male; Olanz	2004
Bipolar II disorder: personality and outcome in two clinical samples. The Australian and New Zealand journal of psychiatry, 2004, Volume: 38, Issue:6 Topics: Adrenergic Uptake Inhibitors; Adult; Bipolar Disorder; Bulimia; Cognitive Behavioral Therapy; Depres	2004
Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:10 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Screening Assays, Antitumor; Dr	2004
Reversed diurnal variation in depression: associations with a differential antidepressant response, tryptophan: large neutral amino acid ratio and serotonin transporter polymorphisms. Psychological medicine, 2005, Volume: 35, Issue:4 Topics: Adult; Affect; Alleles; Amino Acids; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depr	2005
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, C	2005
Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction. Journal of affective disorders, 2005, Volume: 87, Issue:1 Topics: Adult; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug Therapy, Combination; Female; Fl	2005
Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International clinical psychopharmacology, 2005, Volume: 20, Issue:5 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major;	2005
Clinical relevance of depressive symptom improvement in bipolar I depressed patients. Journal of affective disorders, 2006, Volume: 92, Issue:2-3 Topics: Benzodiazepines; Bipolar Disorder; Depression; Diagnostic and Statistical Manual of Mental Disorders	2006
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:5 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cross-Over Studies; Depressive Disor	2006
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:7 Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder	2006
A case of mania associated with fluoxetine. The American journal of psychiatry, 1984, Volume: 141, Issue:2 Topics: Adult; Bipolar Disorder; Clinical Trials as Topic; Depressive Disorder; Female; Fluoxetine; Humans;	1984
Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. Journal of clinical pharmacology, 1995, Volume: 35, Issue:1 Topics: Adolescent; Adult; Amitriptyline; Bipolar Disorder; Chromatography, High Pressure Liquid; Depression	1995
Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts. European archives of psychiatry and clinical neuroscience, 1994, Volume: 244, Issue:4 Topics: Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug A	1994
Are SSRI antidepressants a clinically homogeneous class of compounds? Lancet (London, England), 1994, Jul-09, Volume: 344, Issue:8915 Topics: Adult; Aged; Bipolar Disorder; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Selective	1994
Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. The Journal of clinical psychiatry, 1993, Volume: 54, Issue:9 Topics: Adult; Amoxapine; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Disorder; Depressi	1993
A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. International clinical psychopharmacology, 1993,Winter, Volume: 8, Issue:4 Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Do	1993
Comparison of manic switch onset during fluoxetine and trazodone treatment. Biological psychiatry, 1993, Mar-15, Volume: 33, Issue:6 Topics: Adult; Bipolar Disorder; Depressive Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Male;	1993
Sleep deprivation hastens the antidepressant action of fluoxetine. European archives of psychiatry and clinical neuroscience, 1997, Volume: 247, Issue:2 Topics: Adult; Bipolar Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Sleep Deprivation	1997
Lamotrigine in rapid-cycling bipolar disorder. The Journal of clinical psychiatry, 1997, Volume: 58, Issue:12 Topics: Adult; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combination; F	1997
Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. Journal of child and adolescent psychopharmacology, 1998, Volume: 8, Issue:1 Topics: Adolescent; Antidepressive Agents, Second-Generation; Bipolar Disorder; Child; Depressive Disorder;	1998
Bipolar depression and antidepressant-induced mania: a naturalistic study. The Journal of clinical psychiatry, 1998, Volume: 59, Issue:7 Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Disorder; C	1998
Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:6 Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; C	1998
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. The Journal of clinical psychiatry, 2001, Volume: 62, Issue:4 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Double-Blind Me	2001
Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT. The journal of ECT, 2001, Volume: 17, Issue:2 Topics: Aged; Bipolar Disorder; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relatio	2001
Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:2 Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Bipolar Disorder;	2002
A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. International clinical psychopharmacology, 1989, Volume: 4, Issue:4 Topics: Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Female; Fluoxetine; Humans; Imiprami	1989

Article	Year
Fatal intoxication with antidepressants: a case with many culprits. Forensic science, medicine, and pathology, 2018, Volume: 14, Issue:2 Topics: Adult; Bipolar Disorder; Cardiomyopathy, Hypertrophic; Citalopram; Fluoxetine; Genotype; Heterozygot	2018
FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate. The international journal of neuropsychopharmacology, 2018, 04-01, Volume: 21, Issue:4 Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Drug Therapy, Co	2018
Looking for bipolarity in antidepressant discontinuation manic states: Update and diagnostic considerations of the phenomenon. Journal of affective disorders, 2018, 08-01, Volume: 235 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Child; Citalopram; Cyclothy	2018
Lithium and fluoxetine regulate the rate of phosphoinositide synthesis in neurons: a new view of their mechanisms of action in bipolar disorder. Translational psychiatry, 2018, 08-31, Volume: 8, Issue:1 Topics: Animals; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Cerebral Cort	2018
Antidepressant Prescription Patterns in Bipolar Disorder: a Nationwide, Register-based Study in Korea. Journal of Korean medical science, 2018, Nov-12, Volume: 33, Issue:46 Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disor	2018
Increase in pharmacodynamic tolerance after repeated antidepressant trials in treatment-responsive bipolar I depressed subjects: An exploratory study. Psychiatria polska, 2018, Dec-29, Volume: 52, Issue:6 Topics: Adult; Affect; Antidepressive Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Toler	2018
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2019, Volume: 29, Issue:6 Topics: Bipolar Disorder; Delusions; Depression; Depressive Disorder; Emotions; Female; Fluoxetine; Humans;	2019
Fluoxetine-related mania in an adolescent girl diagnosed with selective mutism: A case report. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2020, Volume: 12, Issue:1 Topics: Adolescent; Anxiety Disorders; Bipolar Disorder; Female; Fluoxetine; Humans; Mutism; Selective Serot	2020
Antidepressants and rapid-cycling bipolar II disorder: dogma, definitions and deconstructing discrepant data. The British journal of psychiatry : the journal of mental science, 2013, Volume: 202, Issue:4 Topics: Antidepressive Agents; Bipolar Disorder; Female; Fluoxetine; Humans; Lithium Compounds; Male; Second	2013
Antidepressants in rapid-cycling bipolar disorder. The British journal of psychiatry : the journal of mental science, 2013, Volume: 203, Issue:1 Topics: Antidepressive Agents; Bipolar Disorder; Female; Fluoxetine; Humans; Lithium Compounds; Male; Second	2013
Authors' reply. The British journal of psychiatry : the journal of mental science, 2013, Volume: 203, Issue:1 Topics: Antidepressive Agents; Bipolar Disorder; Female; Fluoxetine; Humans; Lithium Compounds; Male; Second	2013
Manic symptoms as a symptom of antidepressant discontinuation syndrome in a child. Journal of child and adolescent psychopharmacology, 2013, Volume: 23, Issue:7 Topics: Antidepressive Agents; Bipolar Disorder; Child; Female; Fluoxetine; Humans; Substance Withdrawal Syn	2013
When depression doesn't lead with depression. JAMA psychiatry, 2013, Volume: 70, Issue:11 Topics: Anger; Bipolar Disorder; Cyclohexanols; Depression; Depressive Disorder, Major; Emotions; Female; Fl	2013
Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. The international journal of neuropsychopharmacology, 2014, Volume: 17, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord	2014
Pros and cons of approved therapies for bipolar depression and ongoing unmet needs. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10 Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; D	2014
Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania. The international journal of neuropsychopharmacology, 2014, Oct-31, Volume: 18, Issue:2 Topics: Animals; Antidepressive Agents, Second-Generation; Antimanic Agents; Antipsychotic Agents; Aripipraz	2014
Efficacy and tolerability of treatments for bipolar depression. Journal of affective disorders, 2015, Sep-01, Volume: 183 Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dru	2015
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression. The Australian and New Zealand journal of psychiatry, 2015, Volume: 49, Issue:12 Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De	2015
Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:4 Topics: Animals; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Depressive Diso	2016
Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. Journal of affective disorders, 2016, Jan-15, Volume: 190 Topics: Amino Acids; Animals; Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Ex	2016
Does dose-response relationship further support the concept of posttraumatic OCD. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2016, Volume: 28, Issue:1 Topics: Accidents, Traffic; Adult; Bipolar Disorder; Combat Disorders; Dose-Response Relationship, Drug; Flu	2016
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder. Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:1 Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder	2016
Effectiveness of add-on l-methylfolate therapy in a complex psychiatric illness with MTHFR C677 T genetic polymorphism. Asian journal of psychiatry, 2016, Volume: 22 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disor	2016
Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features. Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:2 Topics: Adrenergic alpha-Antagonists; Aged; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Rela	2009
Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar disorders, 2008, Volume: 10, Issue:8 Topics: Adult; Affect; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar	2008
Invited comment. Acta psychiatrica Scandinavica, 2009, Volume: 120, Issue:4 Topics: Bipolar Disorder; Fluoxetine; Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reu	2009
Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis. Clinical therapeutics, 2009, Volume: 31 Pt 1 Topics: Affect; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cost-Benefit Analysis; Dibenzothiaz	2009
Treatment-resistant bipolar depression: towards a new definition. Acta psychiatrica Scandinavica, 2009, Volume: 120, Issue:6 Topics: Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dib	2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10 Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Diso	2009
Is there a role for antidepressants in the treatment of bipolar II depression? The American journal of psychiatry, 2010, Volume: 167, Issue:7 Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bipolar Disorder; Fluoxetine; Human	2010
Antidepressant use in bipolar disorder: continuing an age-old debate. The American journal of psychiatry, 2010, Volume: 167, Issue:11 Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Evidence-Based Medicine; Fluoxetine; Hum	2010
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study. Biological psychiatry, 2011, Feb-15, Volume: 69, Issue:4 Topics: Adult; Analysis of Variance; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Brain Mappin	2011
Hypomania as a genuine side effect of fluoxetine. The Journal of neuropsychiatry and clinical neurosciences, 2011,Summer, Volume: 23, Issue:3 Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety; Bipolar Disorder; Fluoxetine; Humans;	2011
The prevalence of metabolic syndrome in drug-naïve bipolar II disorder patients before and after twelve week pharmacological intervention. Journal of affective disorders, 2013, Mar-20, Volume: 146, Issue:1 Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Mass Index; Diagnostic and Statistical Manual of Men	2013
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon? Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:6 Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship,	2012
Repeated activation of mania by atypical antipsychotics in a patient. BMJ case reports, 2012, Nov-27, Volume: 2012 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combinatio	2012
Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. Developmental medicine and child neurology, 2002, Volume: 44, Issue:10 Topics: Autistic Disorder; Bipolar Disorder; Child; Child, Preschool; Cluster Analysis; Depressive Disorder,	2002
Lithium-induced periodic alternating nystagmus. Neurology, 2003, Jan-28, Volume: 60, Issue:2 Topics: Antidepressive Agents, Second-Generation; Antimanic Agents; Baclofen; Bipolar Disorder; Female; Fluo	2003
Improving identification of treatment effectiveness in bipolar disorders. Bipolar disorders, 2003, Volume: 5, Issue:2 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical Trials as Topic; Fluoxetine; Human	2003
'Use of selective serotonin reuptake inhibitors in children with pervasive developmental disorder: risk of treatment emergent mania'. Developmental medicine and child neurology, 2003, Volume: 45, Issue:5 Topics: Age Factors; Bipolar Disorder; Child; Child Development Disorders, Pervasive; Drug Monitoring; Fluox	2003
Trichotillomania: response to lithium in a person with comorbid bipolar disorder. Human psychopharmacology, 2003, Volume: 18, Issue:7 Topics: Adult; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Female; Fluoxetine; Humans; Lithiu	2003
Olanzapine/Fluoxetine (Symbyax) for bipolar depression. The Medical letter on drugs and therapeutics, 2004, Mar-15, Volume: 46, Issue:1178 Topics: Adult; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans; Olanzapine; Selecti	2004
New drug available for bipolar disorder. The Nurse practitioner, 2004, Volume: 29, Issue:3 Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; D	2004
Fluoxetine-induced mania in an Asian patient. Psychiatry and clinical neurosciences, 2004, Volume: 58, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major; Diagn	2004
Questions & answers. What is Symbyax, the new drug being marketed for the treatment of bipolar depression. The Harvard mental health letter, 2004, Volume: 21, Issue:2 Topics: Antidepressive Agents; Benzodiazepines; Bipolar Disorder; Drug Combinations; Fluoxetine; Humans	2004
Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5 Topics: Alcoholism; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Baclofen; Bipolar Disord	2004
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology, 2005, Volume: 181, Issue:1 Topics: Action Potentials; Animals; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Brain; Drug Syn	2005
Olanzapine and olanzapine-fluoxetine combination treatment and bipolar I depression. Archives of general psychiatry, 2005, Volume: 62, Issue:9 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Codes of Ethics; Drug Therapy, Combination;	2005
Does olanzapine-fluoxetine combination increase the risk of mania in poorly compliant bipolar depressed patients? Southern medical journal, 2005, Volume: 98, Issue:11 Topics: Adult; Benzodiazepines; Bipolar Disorder; Drug Combinations; Female; Fluoxetine; Humans; Patient Com	2005
Does olanzapine have any antidepressant effect? The American journal of psychiatry, 2006, Volume: 163, Issue:10 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combinat	2006
Pulmonary hypertension during lithium therapy: clinical case study. Psychopharmacology bulletin, 2007, Volume: 40, Issue:1 Topics: Antimanic Agents; Bipolar Disorder; Diagnosis, Differential; Drug Therapy, Combination; Echocardiogr	2007
L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. Journal of affective disorders, 2007, Volume: 103, Issue:1-3 Topics: Adult; Bipolar Disorder; Clomipramine; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Co	2007
Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha. International journal of psychiatry in medicine, 2006, Volume: 36, Issue:4 Topics: Adult; Alcoholics Anonymous; Alcoholism; Anticonvulsants; Antidepressive Agents, Second-Generation;	2006
Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations. Journal of neuroscience methods, 2007, Sep-30, Volume: 165, Issue:2 Topics: Animals; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Bipolar Disorder; Data Interpret	2007
The empirical redefinition of the psychometric criteria for remission in bipolar disorder. Journal of affective disorders, 2008, Volume: 106, Issue:1-2 Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug	2008
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar disorders, 2007, Volume: 9, Issue:6 Topics: Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combinat	2007
Deconstructing a medication regimen. Journal of psychiatric practice, 2008, Volume: 14, Issue:2 Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benztropine; Biotransformation; Bipolar Disorder	2008
Hair loss associated with fluoxetine but not with citalopram. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1995, Volume: 40, Issue:6 Topics: Alopecia; Bipolar Disorder; Citalopram; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middl	1995
[Serotonergic syndrome--in combination therapy with lithium and fluoxetine]. Ugeskrift for laeger, 1995, Feb-27, Volume: 157, Issue:9 Topics: Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Lithium Carbonat	1995
Antidepressant-associated mania: a controlled comparison with spontaneous mania. The American journal of psychiatry, 1994, Volume: 151, Issue:11 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bipolar Dis	1994
The combination of fluoxetine and lithium in clinical practice. International clinical psychopharmacology, 1993,Winter, Volume: 8, Issue:4 Topics: Adult; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combin	1993
Fluoxetine--induced mania in a patient with post-stroke depression. The British journal of psychiatry : the journal of mental science, 1993, Volume: 163 Topics: Bipolar Disorder; Cerebrovascular Disorders; Depressive Disorder; Female; Fluoxetine; Humans; Middle	1993
Prader-Willi and bipolar illness. Journal of the American Academy of Child and Adolescent Psychiatry, 1993, Volume: 32, Issue:4 Topics: Adult; Bipolar Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Lithium; Prader-Will	1993
Drug-induced mania. Hospital & community psychiatry, 1993, Volume: 44, Issue:7 Topics: Bipolar Disorder; Clomipramine; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; O	1993
Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine. Journal of clinical psychopharmacology, 1996, Volume: 16, Issue:2 Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antidepressive Agents, Seco	1996
Antidepressant induced mania in obsessive compulsive disorder. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1996, Volume: 6, Issue:1 Topics: Adult; Antidepressive Agents; Bipolar Disorder; Citalopram; Clomipramine; Female; Fluoxetine; Follow	1996
Changes in fine motor retardation in depressed patients treated with fluoxetine. Journal of affective disorders, 1996, Oct-14, Volume: 40, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Attention; Bipolar Disorder; Depr	1996
Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Acta psychiatrica Scandinavica, 1996, Volume: 93, Issue:1 Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Dipeptidy	1996
Response of kleptomania and mixed mania to valproate. The American journal of psychiatry, 1997, Volume: 154, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Comorbidity; Di	1997
A new case of fluoxetine-induced mania in poststroke depression. Clinical neuropharmacology, 1997, Volume: 20, Issue:2 Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cerebrovascular Disorders; Depres	1997
Fluoxetine-induced Raynaud's phenomenon. Biological psychiatry, 1997, Jun-15, Volume: 41, Issue:12 Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Female; Fluoxetine; Humans; Middle Aged;	1997
Existing brain condition may predispose to SSRI-induced extrapyramidal symptoms. The Australian and New Zealand journal of psychiatry, 1997, Volume: 31, Issue:5 Topics: Akathisia, Drug-Induced; Basal Ganglia Diseases; Bipolar Disorder; Cerebral Infarction; Female; Fluo	1997
Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clinical pediatrics, 1998, Volume: 37, Issue:1 Topics: Adult; Anticonvulsants; Bipolar Disorder; Breast Feeding; Carbamazepine; Female; Fluoxetine; Humans;	1998
Medication-induced hypomania in Asperger's disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 1998, Volume: 37, Issue:3 Topics: Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Autistic Disorder; Bipolar Disorder	1998
An adolescent male with multiple paraphilias successfully treated with fluoxetine. Journal of child and adolescent psychopharmacology, 1998, Volume: 8, Issue:3 Topics: Adolescent; Antidepressive Agents, Second-Generation; Bipolar Disorder; Fluoxetine; Humans; Male; Ob	1998
A case report of serotonin syndrome associated with combined nefazodone and fluoxetine. The Journal of clinical psychiatry, 2000, Volume: 61, Issue:2 Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Drug Therapy, Combination; Fluoxetine; H	2000
Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:1 Topics: Antidepressive Agents, Second-Generation; Bipolar Disorder; Dose-Response Relationship, Drug; Female	2001
Mania and tramadol-fluoxetine combination. The American journal of psychiatry, 2001, Volume: 158, Issue:6 Topics: Aged; Analgesics, Opioid; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Female;	2001
Mania associated with mirtazapine augmentation of fluoxetine. Depression and anxiety, 2002, Volume: 15, Issue:1 Topics: Adrenergic alpha-Antagonists; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administratio	2002
Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain injury, 2002, Volume: 16, Issue:4 Topics: Adult; Anti-Anxiety Agents; Bipolar Disorder; Brain Injuries; Buspirone; Depression; Drug Interactio	2002
Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report. Pharmacology & toxicology, 2002, Volume: 90, Issue:5 Topics: Acute Disease; Acute Kidney Injury; Adult; Antimanic Agents; Antipsychotic Agents; Bayes Theorem; Bi	2002
Hypomania induced by fluoxetine? Biological psychiatry, 1992, Jul-01, Volume: 32, Issue:1 Topics: Adult; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxetine;	1992
Fluoxetine and depersonalization syndrome. Psychosomatics, 1992,Summer, Volume: 33, Issue:3 Topics: Bipolar Disorder; Depersonalization; Female; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorder	1992
Antidepressant-induced mania in obsessive-compulsive disorder. The American journal of psychiatry, 1992, Volume: 149, Issue:9 Topics: Bipolar Disorder; Clomipramine; Fluoxetine; Humans; Norepinephrine; Obsessive-Compulsive Disorder; S	1992
Fluoxetine and bupropion treatment of bipolar disorder, type II, associated with GAD. The Journal of clinical psychiatry, 1992, Volume: 53, Issue:2 Topics: Anxiety Disorders; Bipolar Disorder; Bupropion; Drug Therapy, Combination; Fluoxetine; Humans; Infan	1992
Mania associated with fluoxetine treatment in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 1992, Volume: 31, Issue:2 Topics: Adolescent; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Female; Fluoxet	1992
A case of mania as a result of fluoxetine-marijuana interaction. The Journal of clinical psychiatry, 1991, Volume: 52, Issue:6 Topics: Adult; Bipolar Disorder; Dronabinol; Drug Interactions; Female; Fluoxetine; Humans; Marijuana Smokin	1991
A potential drug interaction between fluoxetine and valproic acid. Journal of clinical psychopharmacology, 1991, Volume: 11, Issue:6 Topics: Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; Intellec	1991
Fluoxetine-induced mania in a suicidal depressed patient. DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:12 Topics: Adult; Bipolar Disorder; Female; Fluoxetine; Humans; Suicide, Attempted	1991
Fluoxetine-induced mania in a patient with obsessive-compulsive disorder. The American journal of psychiatry, 1991, Volume: 148, Issue:10 Topics: Adult; Bipolar Disorder; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorder	1991
Mania induced by fluoxetine in an adolescent patient. The American journal of psychiatry, 1991, Volume: 148, Issue:10 Topics: Adolescent; Bipolar Disorder; Depressive Disorder; Fluoxetine; Humans; Male	1991
Fluoxetine and parkinsonism in patients taking carbamazepine. The American journal of psychiatry, 1991, Volume: 148, Issue:11 Topics: Aged; Bipolar Disorder; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Female; Fluoxet	1991
Hypomania with fluoxetine. Journal of the American Academy of Child and Adolescent Psychiatry, 1991, Volume: 30, Issue:5 Topics: Adjustment Disorders; Bipolar Disorder; Child; Fluoxetine; Humans; Male; Substance-Related Disorders	1991
Fluoxetine side effects. Journal of the American Academy of Child and Adolescent Psychiatry, 1991, Volume: 30, Issue:5 Topics: Adolescent; Arousal; Bipolar Disorder; Depressive Disorder; Fluoxetine; Hospitalization; Humans; Mal	1991
Depersonalization syndrome induced by fluoxetine. Psychosomatics, 1991,Fall, Volume: 32, Issue:4 Topics: Adult; Arousal; Bipolar Disorder; Depersonalization; Female; Fluoxetine; Humans	1991
Fluoxetine treatment of bipolar II depression. Journal of clinical psychopharmacology, 1991, Volume: 11, Issue:1 Topics: Adult; Aged; Bipolar Disorder; Female; Fluoxetine; Humans; Male; Middle Aged	1991
Interaction of fluoxetine and selegiline. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 1990, Volume: 35, Issue:6 Topics: Bipolar Disorder; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine	1990
Antidepressant-induced mania. The American journal of psychiatry, 1990, Volume: 147, Issue:11 Topics: Adult; Antidepressive Agents; Bipolar Disorder; Diagnosis, Differential; Female; Fluoxetine; Humans;	1990
Fluoxetine-induced mania. The Journal of clinical psychiatry, 1990, Volume: 51, Issue:12 Topics: Adult; Bipolar Disorder; Carbamazepine; Drug Therapy, Combination; Female; Fluoxetine; Humans; Lithi	1990
Fluoxetine in the treatment of cyclic mood disorders. Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Universite d'Ottawa, 1990, Volume: 15, Issue:4 Topics: Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination; Fluoxetine;	1990
Mania in a panic disorder patient treated with fluoxetine. The American journal of psychiatry, 1990, Volume: 147, Issue:8 Topics: Adult; Alprazolam; Anxiety Disorders; Bipolar Disorder; Fear; Fluoxetine; Humans; Male; Panic	1990
A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. The American journal of psychiatry, 1989, Volume: 146, Issue:2 Topics: Adult; Ataxia; Bipolar Disorder; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Huma	1989
Mania resulting from lithium-fluoxetine combination. The American journal of psychiatry, 1989, Volume: 146, Issue:12 Topics: Adult; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Female; Fluoxetine; Humans; L	1989
Mania during fluoxetine treatment for recurrent depression. The American journal of psychiatry, 1989, Volume: 146, Issue:12 Topics: Age Factors; Aged; Bipolar Disorder; Depressive Disorder; Fluoxetine; Humans; Male; Middle Aged; Psy	1989
Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. The Journal of clinical psychiatry, 1989, Volume: 50, Issue:12 Topics: Adult; Aged; Antidepressive Agents; Bipolar Disorder; Depressive Disorder; Drug Therapy, Combination	1989
Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. The American journal of psychiatry, 1989, Volume: 146, Issue:3 Topics: Adult; Basal Ganglia Diseases; Bipolar Disorder; Drug Interactions; Drug Therapy, Combination; Femal	1989
Mania induced by fluoxetine. The American journal of psychiatry, 1989, Volume: 146, Issue:11 Topics: Aged; Bipolar Disorder; Depressive Disorder; Female; Fluoxetine; Humans	1989
A case of mania induced by high-dose fluoxetine treatment. The American journal of psychiatry, 1986, Volume: 143, Issue:5 Topics: Adult; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Fluoxetine; Humans;	1986
Mania precipitated by fluoxetine. The American journal of psychiatry, 1987, Volume: 144, Issue:12 Topics: Adult; Bipolar Disorder; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; Propyla	1987
A second case of mania associated with fluoxetine. The American journal of psychiatry, 1985, Volume: 142, Issue:2 Topics: Adult; Bipolar Disorder; Depressive Disorder; Fluoxetine; Humans; Male; Obsessive-Compulsive Disorde	1985

fluoxetine and Bipolar Disorder